{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:14:55Z","timestamp":1791065695367,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10637-010-9549-5","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T03:52:33Z","timestamp":1285645953000},"page":"702-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Treatment of bevacizumab-induced hypertension by amlodipine"],"prefix":"10.1007","volume":"30","author":[{"given":"Olivier","family":"Mir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Ropert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Cabanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Billemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,29]]},"reference":[{"issue":"5","key":"9549_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20(5):807\u2013815","journal-title":"Ann Oncol"},{"key":"9549_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9310-0","author":"JB Lee","year":"2009","unstructured":"Lee JB, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee ES, Kim YH, Kim JS, Seo JH (2009) Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs. doi:10.1007\/s10637-009-9310-0","journal-title":"Invest New Drugs"},{"issue":"5","key":"9549_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ajh.2010.25","volume":"23","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23(5):460\u2013468","journal-title":"Am J Hypertens"},{"issue":"5","key":"9549_CR4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/annonc\/mdp206","volume":"20","author":"O Mir","year":"2009","unstructured":"Mir O, Ropert S, Alexandre J, Goldwasser F (2009) Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20(5):967\u2013970","journal-title":"Ann Oncol"},{"issue":"2","key":"9549_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2):186\u2013193","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"9549_CR6","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232\u20131239","journal-title":"J Natl Cancer Inst"},{"key":"9549_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.03.003","author":"JJ Monsuez","year":"2010","unstructured":"Monsuez JJ, Charniot JC, Vignat N, Artigou JY (2010) Cardiac side-effects of cancer chemotherapy. Int J Cardiol. doi:10.1016\/j.ijcard.2010.03.003","journal-title":"Int J Cardiol"},{"key":"9549_CR8","doi-asserted-by":"crossref","unstructured":"Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC et al: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:1\u20139","DOI":"10.1093\/jnci\/djq091"},{"issue":"3","key":"9549_CR9","doi-asserted-by":"publisher","first-page":"39A","DOI":"10.1016\/0002-9149(94)90273-9","volume":"73","author":"JF Burris","year":"1994","unstructured":"Burris JF, Allenby KS, Mroczek WJ (1994) The effect of amlodipine on ambulatory blood pressure in hypertensive patients. Am J Cardiol 73(3):39A\u201343A","journal-title":"Am J Cardiol"},{"issue":"3","key":"9549_CR10","doi-asserted-by":"publisher","first-page":"2A","DOI":"10.1016\/0002-9149(94)90268-2","volume":"73","author":"R Burges","year":"1994","unstructured":"Burges R, Moisey D (1994) Unique pharmacologic properties of amlodipine. Am J Cardiol 73(3):2A\u20139A","journal-title":"Am J Cardiol"},{"issue":"3","key":"9549_CR11","doi-asserted-by":"publisher","first-page":"10A","DOI":"10.1016\/0002-9149(94)90269-0","volume":"73","author":"DR Abernethy","year":"1994","unstructured":"Abernethy DR (1994) An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 73(3):10A\u201317A","journal-title":"Am J Cardiol"},{"issue":"6","key":"9549_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","volume":"21","author":"European Society of Hypertension-European Society of Cardiology Guidelines Committee","year":"2003","unstructured":"European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21(6):1011\u20131053","journal-title":"J Hypertens"},{"issue":"2","key":"9549_CR13","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00004872-200305002-00003","volume":"21","author":"E O\u2019Brien","year":"2003","unstructured":"O\u2019Brien E (2003) Ambulatory blood pressure measurement is indispensable to good clinical practice. J Hypertens Suppl 21(2):S11\u2013S18","journal-title":"J Hypertens Suppl"},{"issue":"3","key":"9549_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176\u2013181","journal-title":"Semin Radiat Oncol"},{"issue":"23","key":"9549_CR15","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"key":"9549_CR16","doi-asserted-by":"crossref","unstructured":"Lowery M, Power D, Behbehani A, Carney D, Mc Caffrey JA (2007) Hypertension is a significant adverse effect of bevacizumab treatment. J Clin Oncol 25 (18S)(18S):Abstract 14134","DOI":"10.1200\/jco.2007.25.18_suppl.14134"},{"issue":"5B","key":"9549_CR17","first-page":"3465","volume":"27","author":"A Pande","year":"2007","unstructured":"Pande A, Lombardo J, Spangenthal E, Javle M (2007) Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27(5B):3465\u20133470","journal-title":"Anticancer Res"},{"issue":"2","key":"9549_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46(2):439\u2013448","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"9549_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00003495-200565002-00005","volume":"65","author":"RR Wenzel","year":"2005","unstructured":"Wenzel RR (2005) Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 65(Suppl 2):29\u201339","journal-title":"Drugs"},{"key":"9549_CR20","doi-asserted-by":"crossref","unstructured":"Hedrick E, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Dong W, Suzuki S, Sugrue M, Grothey A (2006) Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 24 (18S)(18S):Abstract 3536","DOI":"10.1200\/jco.2006.24.18_suppl.3536"},{"issue":"36","key":"9549_CR21","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","volume":"27","author":"MH Langenberg","year":"2009","unstructured":"Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A et al (2009) Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 27(36):6152\u20136159","journal-title":"J Clin Oncol"},{"issue":"2","key":"9549_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1291\/hypres.28.147","volume":"28","author":"S Miura","year":"2005","unstructured":"Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K (2005) Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor\/fetal liver kinase-1\/NO pathway. Hypertens Res 28(2):147\u2013153","journal-title":"Hypertens Res"},{"key":"9549_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9514-3","author":"C Gomo","year":"2010","unstructured":"Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B (2010) Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. doi:10.1007\/s10637-010-9514-3","journal-title":"Invest New Drugs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9549-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9549-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9549-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9549-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:18:46Z","timestamp":1678558726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9549-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,29]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["9549"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9549-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,29]]},"assertion":[{"value":"15 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}